1. Home
  2. VRTX vs SO Comparison

VRTX vs SO Comparison

Compare VRTX & SO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • SO
  • Stock Information
  • Founded
  • VRTX 1989
  • SO 1946
  • Country
  • VRTX United States
  • SO United States
  • Employees
  • VRTX N/A
  • SO N/A
  • Industry
  • VRTX EDP Services
  • SO Power Generation
  • Sector
  • VRTX Technology
  • SO Utilities
  • Exchange
  • VRTX Nasdaq
  • SO Nasdaq
  • Market Cap
  • VRTX 115.6B
  • SO 100.3B
  • IPO Year
  • VRTX 1991
  • SO N/A
  • Fundamental
  • Price
  • VRTX $445.37
  • SO $91.22
  • Analyst Decision
  • VRTX Buy
  • SO Hold
  • Analyst Count
  • VRTX 26
  • SO 15
  • Target Price
  • VRTX $510.48
  • SO $93.36
  • AVG Volume (30 Days)
  • VRTX 1.3M
  • SO 5.3M
  • Earning Date
  • VRTX 07-31-2025
  • SO 07-31-2025
  • Dividend Yield
  • VRTX N/A
  • SO 3.22%
  • EPS Growth
  • VRTX N/A
  • SO 8.04
  • EPS
  • VRTX N/A
  • SO 4.17
  • Revenue
  • VRTX $11,099,700,000.00
  • SO $27,853,000,000.00
  • Revenue This Year
  • VRTX $10.48
  • SO $7.01
  • Revenue Next Year
  • VRTX $10.69
  • SO $4.47
  • P/E Ratio
  • VRTX N/A
  • SO $22.02
  • Revenue Growth
  • VRTX 8.98
  • SO 9.58
  • 52 Week Low
  • VRTX $377.85
  • SO $76.96
  • 52 Week High
  • VRTX $519.88
  • SO $94.45
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 45.87
  • SO 57.32
  • Support Level
  • VRTX $436.81
  • SO $89.47
  • Resistance Level
  • VRTX $451.88
  • SO $91.29
  • Average True Range (ATR)
  • VRTX 9.25
  • SO 1.26
  • MACD
  • VRTX 0.32
  • SO 0.20
  • Stochastic Oscillator
  • VRTX 28.02
  • SO 89.26

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About SO Southern Company (The)

Southern is one of the largest utilities in the US. The company serves 9 million customers with vertically integrated electric utilities in three states and natural gas distribution utilities in four states. It owns 50 gigawatts of rate-regulated generating capacity, primarily for serving customers in Georgia, Alabama, and Mississippi. Subsidiary Southern Power owns 13 gigawatts of natural gas generation and renewable energy across the U.S. and sells the electricity primarily under long-term contracts.

Share on Social Networks: